The Impact of Aetna’s Proposed Medicare Part D Stand-Alone Prescription Drug Plan Divestiture to WellCare

May 31, 2019by Richard M. Scheffler The purpose of this testimony is twofold. First, I will provide background information on the Medicare Part D stand-alone prescription drug plan (PDP) market and present recent market concentration trends. Second, I will demonstrate how Aetna’s proposed divestiture of its PDPs to WellCare would increase PDP market concentration. *This paper was revised and reposted on June 17, 2019